Pluristem Therapeutics Given New $3.00 Price Target at Jefferies Group (PSTI)

Share on StockTwits

Pluristem Therapeutics (NASDAQ: PSTI) had its target price decreased by Jefferies Group from $3.50 to $3.00 in a research note released on Wednesday morning, StockRatingsNetwork.com reports. They currently have a hold rating on the stock.

“On 6/4/13, PSTI announced FDA has placed its Phase 2 for lead stem-cell product candidate PLX-PAD on clinical hold in light of a single episode of serious allergic reaction, creating further uncertainty regarding the timing of Phase 3 initiation (by ~YE13 previously). FDA will issue formal letter with questions and requests for information within the next month.,” the firm’s analyst wrote.

Shares of Pluristem Therapeutics (NASDAQ: PSTI) traded down 1.00% during mid-day trading on Wednesday, hitting $2.96. Pluristem Therapeutics has a one year low of $2.26 and a one year high of $5.00. The stock’s 50-day moving average is currently $3.09. The company’s market cap is $173.6 million.

A number of other firms have also recently commented on PSTI. Analysts at Maxim Group downgraded shares of Pluristem Therapeutics from a buy rating to a hold rating in a research note to investors on Tuesday. Analysts at MLV Capital initiated coverage on shares of Pluristem Therapeutics in a research note to investors on Friday, May 31st. They set a buy rating and a $4.50 price target on the stock.

Pluristem Therapeutics Inc. (NASDAQ: PSTI) is a bio-therapeutics company engaged in the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Latest News

Photo leaked on Internet Shows Blackberry Operated by Android
Photo leaked on Internet Shows Blackberry Operated by Android
Xiaomi Sales of Smartphones Not So Disappointing
Xiaomi Sales of Smartphones Not So Disappointing
Celgene Investing $1 Billion in Juno Therapeutics
Celgene Investing $1 Billion in Juno Therapeutics
Greece Considering Capital Controls and Bank Closures
Greece Considering Capital Controls and Bank Closures
Nike Earnings Run Past Estimates
Nike Earnings Run Past Estimates
Ikea Raising Minimum Wage for U.S. Workers
Ikea Raising Minimum Wage for U.S. Workers


Advertisement
Advertisement
© 2006-2015 Ticker Report. Google+.